OMKARCHEM

Omkar Speciality Chemicals Limited has informed the Exchange regarding The Composite Scheme of Arrangement- Allotment of Equity Shares by Lasa Supergenerics Limited (Resulting Company).

Omkar Speciality Chemicals Limited has informed the Exchange that regarding a Filing of A Patent Application for a Novel Process for Coumarin.

Omkar Speciality Chemicals Limited has informed the Exchange that the Management would like to inform all stake holders that the Company has framed concrete plans for its business expansion by scaling up its activities in the existing segments like pharmaceuticals and related areas. The Company would further like to penetrate into segments like fragrances & flavours, foods & beverages, etc. in which new products will be launched in immediate future. These products will be having end application in FMCG sector. The Company has already tapped opportunities in these segments in domestic and overs

Omkar Speciality Chemicals Limited has informed the Exchange regarding Cost Of Acquisition of the shares of Omkar Speciality Chemicals Limited and Lasa Supergenerics Limited.

Omkar Speciality Chemicals Limited has submitted to the Exchange a copy of Transcript of Conference Call .

Omkar Speciality Chemicals Limited has informed the Exchange regarding Update on Composite Scheme of Arrangement between Omkar Speciality Chemicals Limited and Lasa Laboratory Private Limited and Urdhwa Chemicals Company Private Limited and Rishichem Research Limited and Desh Chemicals Private Limited and Lasa Supergenerics Limited and their respective Shareholders and Creditors.

Omkar Speciality Chemicals Limited has informed the Exchange regarding the Update on Composite Scheme of Arrangement between M/s Omkar Speciality Chemicals Limited and M/s Lasa Laboratory Private Limited and M/s Urdhwa Chemicals Company Private Limited and M/s Rishichem Research Limited and M/s Desh Chemicals Private Limited and M/s Lasa Supergenerics Limited and their respective Shareholders and Creditors.

Omkar Speciality Chemicals Limited has informed the Exchange regarding the Notice of hearing of petition filed for Scheme of Arrangement.

Omkar Speciality Chemicals Limited has submitted to the Exchange a copy of Annual Report- 2015-16

Omkar Speciality Chemicals Limited has informed the Exchange regarding Conference Call.

Omkar Speciality Chemicals Limited has informed the Exchange that Lasa Laboratory Private Limited, wholly owned subsidiary of the Company, has purchased plot no. C-105/1 admeasuring 5200 Sq. mtrs. (adjoining the existing plot) in "Industrial" Zone of the Mahad Industrial Area, Village: Birwadi,Tai. Mahad, Dist.Raigad for enhancing production capacity of veterinary API.

Omkar Speciality Chemicals Limited has submitted to the Exchange a copy of the transcript of Concall held on May 25, 2016 for Audited Financial Results of the Company for the quarter and year ended March 31, 2016.

Omkar Speciality Chemicals Limited has informed the Exchange that Disclosure under Regulation 31(1) of SEBI (SAST) Regulations, 2011

Omkar Speciality Chemicals Limited has informed the Exchange regarding Intimation of Conference Call.

Omkar Speciality Chemicals Limited has informed the Exchange regarding Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

Omkar Speciality Chemicals Limited has informed the Exchange that a Conference Call is scheduled to be held on May 25, 2016, for the Audited Financial Results of the Company for the quarter and year ended March 31, 2016.

Omkar Speciality Chemicals Limited has submitted the Exchange a copy of transcript of Conference Call April 12, 2016.

Omkar Speciality Chemicals Limited has informed the Exchange regarding Intimation of Incorporation of a Wholly Owned Subsidiary Company.

Omkar Speciality Chemicals Limited has informed the Exchange regarding Transcript of Earnings Conference Call.

Omkar Speciality Chemicals Limited has informed the Exchange regarding Intimation of Conference Call for Unaudited Financial Results for the quarter and nine months ended December 31,2015

Omkar Speciality Chemicals Limited has informed the Exchange about the Intimation of conference call for the unaudited financial results for the quarter and nine months ended December 31, 2015.

Omkar Speciality Chemicals Limited has informed the Exchange vide letter dated February 09, 2016 regarding Conference Call.

Omkar Speciality Chemicals Limited has informed the Exchange regarding Conference call for Unaudited Financial Results for the quarter and nine months ended December 31, 2015.

Omkar Speciality Chemicals Limited has informed the Exchange regarding the company has received Environment Clearance.

Omkar Speciality Chemicals Limited has informed the Exchange regarding Contact Details of Key Managerial Personnel authorised for determining materiality of any event or transaction or information and for the purpose of making disclosures to Stock Exchange(s).

Omkar Speciality Chemicals Limited has informed the Exchange that this refers to earlier letter dated October 23, 2015, about the resignation of Mr. Nirav Momaya, Company Secretary & Compliance Officer, of the Company. Mr. Sunny Pagare, has been appointed as Compliance Officer of the Company w.e.f. December 4, 2015 under Regulation 6(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Omkar Speciality Chemicals Limited has informed the Exchange regarding the Details of Key Managerial Personnel authorised for determining materiality of any event or transaction or information and for the purpose of making disclosures to Stock Exchange(s).

Omkar Speciality Chemicals Limited has informed the Exchange w.r.t to their letter dated October 23, 2015 for submitting the financial results of the company as adopted and approved by the Board of Directors in the meeting held on October 23, 2015.There was a typographical error in the financial data (EPS) sent to the Exchange, which is now corrected in the revised file attached. Enclosed is the revised financials.

Omkar Speciality Chemicals Limited has informed the Exchange that Omkar Speciality Chemicals Limited (OSCL), a manufacturer of Speciality Chemicals, Intermediates and Active Pharmaceuticals Ingredients (APIs), has filed one more application for the grant of Patent for preparing 4-BROMO-ORTHO-PHENYLENE-DIAMINE, a key precursor for making of the drug namely Ledipasvir. Ledipasvir is a drug for the treatment of Hepatitis C.

Omkar Speciality Chemicals Limited has submitted to the Exchange a copy of revised Financial Results (Standalone and Consolidated) for the financial year ended on March 31, 2015.

Omkar Speciality Chemicals Limited has informed the Exchange that Mr. Pravin S. Herlekar, Promoter and Chairman & Managing Director of OSCL has been honored for his dedicated services to the Chemical Industry and developing various molecules through research and development activity in this field, by Free Press Journal group, at the hands of Mr. Devendra Fadnavis, Chief Minister of State of Maharashtra, in the presence of Hon'ble Shri Ram Naik, Governor of State of Uttar Pradesh, on April 30, 2015.

Omkar Speciality Chemicals Limited has informed the Exchange regarding Company's bags concrete indents worth Rs. 100 crore.

Omkar Speciality Chemicals Limited has informed the Exchange that regarding Commissioning of the Unit No VI, located at Plot No.B-15 & B-15, Lote Parshuram MIDC, Chiplun, Dist : Ratnagiri, State: Maharashtra.

Omkar Speciality Chemicals Limited has informed the Exchange that Company's claim for process patent for an Advance Intermediate namely "BENZENESELENINIC ANHYDRIDE" , having special applications in pharmaceutical industry has been accepted by the Patents Office, Govt. of India. A copy of the Certificate is enclosed herewith.

Omkar Speciality Chemicals Limited has informed the Exchange that the wholly owned subsidiary, M/s. Lasa Laboratory Private Limited, has been successful in obtaining the Certificate of Suitability from European Directorate for the Quality of Medicines & Healthcare (EDQM), vide certificate No. R0-CEP 2013-184-Rev 00 dated 15th October, 2014, for selling its product FENBENDAZOLE . This certificate will be useful for the Company in marketing its above product to regulatory customers in the European Market for Veterinary use.

Omkar Speciality Chemicals Limited has informed the Exchange that Company is pleased to invite the Shareholders of the Company, to visit its Plants located in the vicinity of Badlapur on November 1, 2014. This Plant visit is a half day program and is limited for 100 people. Shareholders who are interested can make reservation by sending an email at investor@omkarchemicals.com on or before October 20, 2014.

Omkar Speciality Chemicals Limited has informed the Exchange that the Company's claim for process patent for an Advance Intermediate namely "5-IODO-2-METHYLBENZOIC ACID", having special applications in pharmaceutical industry has been accepted by the Patents Office, Govt. of India, vide their Certificate dated September 10, 2014.

Omkar Speciality Chemicals Limited has informed the Exchange that all business set out in the Notice of Annual General Meeting may be transacted by Electronic Voting. The e-voting period commences on August 03, 2014 and ends on August 05, 2014.

Omkar Speciality Chemicals Limited has informed the Exchange that "the new project at our Unit No. VI, located at Plot No.B-15 & B-16, Lote Parshuram Industrial Area, Taluka Khed, Dist: Ratnagiri, PIN - 415722, State: Maharashtra, has been completed and we propose to start the trial runs followed up by regular commercial production very shortly. This plant, with a capacity of 300 MTs per annum, will manufacture advance intermediates for the pharma industry catering to essential life-saving drugs with the state of the art facility for production and quality control. This facility will also cont

Omkar Speciality Chemicals Limited has informed the Exchange, vide letter dated November 23, 2013 regarding the "Acquisition of Plot(s)".

Omkar Speciality Chemicals Limited has informed the Exchange that the Shareholding of the Promoter's Group has been increased from 11,858,816 shares (60.42%) as on September 30, 2013 to 12,569,080 shares (64.04%) as on November 15, 2013, through secondary market acquisitions. Further, the Company has informed that, IDFC Premier Equity Fund (Mutual Fund) has acquired 880,510 shares (4.49%) of the Company in the recent past, from the secondary market.

Omkar Speciality Chemicals Limited has informed the Exchange that "M/s Omkar Speciality Chemicals Limited has acquired the rights of the Plot No. W-93(A), admeasuring about 720 sq.mtrs situated at MIDC, Badlapur (East), Thane - 421503, which earlier belonged to M/s Desh Chemicals Pvt. Ltd., wholly owned subsidiary of the Company, for the operational benefits of the Company".

Omkar Speciality Chemicals Limited has informed the Exchange vide letter dated December 24, 2012 regarding "Commissioning of Our New Facility at Urdhwa Chemicals Co. Pvt. Ltd. (Wholly Owned Subsidiary), Chiplun".

Omkar Speciality Chemicals Limited has informed the Exchange vide letter dated November 30, 2012 regarding "Updates on Utilization of our IPO proceeds and status of our various projects".

Omkar Speciality Chemicals Limited has informed the Exchange that Ms. Pooja Dandekar Assistant Company Secretary will sign the documents as a Compliance officer of the Company in absence of Mrs. Swapnali Puranik, Company Secretary & compliance officer of the Company.

Omkar Speciality Chemicals Limited has informed the Exchange that a Press Conference of the Company will be held on May 14, 2012 to discuss about the Company's various projects and prospects and also to explore the possibilities of investments by the Company in the state of Goa if any in the Company's existing line of operations such as setting-up a R&D Facility etc.

Omkar Speciality Chemicals Limited has informed the Exchange that the Company has been accorded the coveted status of 'Star Export House' in accordance with the provisions of the Foreign Trade Policy, 2009-2014 by the Ministry of Commerce and Industry, Department of Commerce, Government of India. This makes OSCL eligible for many privileges that will help enhance its business and exports revenues. This is the highest recognition given to OSCL, based on its cumulative value of exports in the past couple of years, along with consistent export track record and continual growth in turnover and for

Omkar Speciality Chemicals Limited has informed the Exchange that a Press Conference of the Company will be held on April 10, 2012 to discuss about the Company's venture into pharmaceutical business with its recent acquisition of LASA Laboratory Private Limited.

Omkar Speciality Chemicals Limited has informed the Exchange that the Company have forayed into pharmaceutical business with the Company's recent acquisition of LASA Laboratory Private Limited located at Mahad in Raigad district, which has been an established player in the anthelmintic/ veterinary API segment with state-of-the-art API manufacturing facility.

Omkar Speciality Chemicals Limited has informed the Exchange that the Company have set-up an R&D Centre at the Company's Corporate Office, B-34, MIDC, Badlapur, Dist: Thane - 421503, State: Maharashtra. The facilities and infrastructure at the Company's R&D Centre have been audited by the Government of India Ministry of Science and Technology, Department of Science and Industrial Research, New Delhi and the Company have been accorded the recognition by Department of Scientific and Industrial Research vide their letter dated November 28, 2011 in this regard. This R&D Centre will help the Compan